The ROE as of November 2024 (TTM) for G1 Therapeutics, Inc. (GTHX) is 26.28%

According to G1 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 26.28%. This represents a change of -220.21% compared to the average of -21.86% of the last 4 quarters.

G1 Therapeutics, Inc. (GTHX) Historical ROE (quarterly & annually)

How has GTHX ROE performed in the past?

The mean historical ROE of G1 Therapeutics, Inc. over the last ten years is -66.15%. The current 26.28% ROE has changed -139.73% with respect to the historical average. Over the past ten years (40 quarters), GTHX's ROE was at its highest in in the June 2023 quarter at 15.14%. The ROE was at its lowest in in the June 2022 quarter at -63.22%.

G1 Therapeutics, Inc. (GTHX) ROE by Quarter and Year

Discovering the peaks and valleys of G1 Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

G1 Therapeutics, Inc. (GTHX) Average ROE

How has GTHX ROE performed in the past?

The current ROE of G1 Therapeutics, Inc. (GTHX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

G1 Therapeutics, Inc. (GTHX) ROE vs. Peers

How is GTHX’s ROE compared to its peers?

G1 Therapeutics, Inc.’s ROE is greater than Allogene Therapeutics, Inc. (-58.07%), less than Heron Therapeutics, Inc. (76.79%), greater than Annexon, Inc. (-38.99%), greater than Sangamo Therapeutics, Inc. (-266.47%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than HOOKIPA Pharma Inc. (-49.25%), greater than Mereo BioPharma Group plc (-69.11%), less than Galera Therapeutics, Inc. (21.95%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), less than Atara Biotherapeutics, Inc. (965.52%), greater than Fate Therapeutics, Inc. (-45.88%), greater than Sana Biotechnology, Inc. (-94.47%), greater than Caribou Biosciences, Inc. (-45.46%), greater than Arcus Biosciences, Inc. (-45.59%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Blueprint Medicines Corporation (-47.66%), greater than Axsome Therapeutics, Inc. (-234.35%), greater than PDS Biotechnology Corporation (-139.57%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), less than Coherus BioSciences, Inc. (0.40%), greater than Larimar Therapeutics, Inc. (-35.87%), less than Puma Biotechnology, Inc. (41.50%), greater than MacroGenics, Inc. (-89.42%),

Build a custom stock screener for G1 Therapeutics, Inc. (GTHX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like G1 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

G1 Therapeutics, Inc. (GTHX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like G1 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.